An Observational, Prospective Cohort Study to Evaluate Safety of Remsima® Subcutaneous in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis (CT-P13 4.8)First published 20/12/2022 Last updated 23/04/2024 EU PAS number: EUPAS50207StudyOngoing